Practical management of chronic lymphocytic leukemia with acalabrutinib

Practical management of chronic lymphocytic leukemia with acalabrutinib

Source : https://www.tandfonline.com/doi/full/10.1080/10428194.2022.2098289

Abstract Abstract Treatment of chronic lymphocytic leukemia (CLL) has been transformed in the past two decades. The introduction of targeted therapies has improved patient outcomes and the deliverability of effective therapies. Making the best use of the next wave of Bruton's tyrosine kinase (BTK) inhibitors requires an understanding of the nuances that separate the drugs in this class of agents.


Conclusion: Acalabrutinib represents a well-tolerated and effective alternative to ibrutinib in the management of CLL.